Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ONCOSEC MEDICAL IncONCS · Entity 117092 | Director | June 28, 2021 | June 29, 2021 |
| Radius Health, Inc.RDUS · Entity 124173 | Director · President & CEO | February 17, 2017 | February 22, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ONCOSEC MEDICAL Inc
Report date June 28, 2021 · Filed June 29, 2021
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.16 · Expires 2031-06-28 | Direct | 25,000 |
Reported balance
After 2021-06-28 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2021-06-28 · Grant · Acquired 25,000 · Balance 25,000 F1: The option will vest in equal quarterly installments over the next year. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in equal quarterly installments over the next year.
Radius Health, Inc.
Report date February 17, 2017 · Filed February 22, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $45.65 · Expires 2027-02-16 | Direct | 187,800 |
Reported balance
After 2017-02-17 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2017-02-17 · Grant · Acquired 187,800 · Balance 187,800 F1: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. |
Filing footnotes · ownership attribution and instrument terms
F1: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years.
Past disclosures · reporting ended (1)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Eloxx Pharmaceuticals, Inc.
Report date February 29, 2020 · Filed March 03, 2020
Section 16 reporting ended · disclosed 2020-03-03. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 267,552 |
Reported balance
After 2020-02-29 transaction · row 1
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 1 · 2020-02-29 · Exercise / conversion · Acquired 76,806 · Balance 267,552 F1: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F2: Of this amount, 252,552 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. |
| Common StockSEC Table I · non-derivative | Direct | 244,267 |
Reported balance
After 2020-02-29 transaction · row 2
Account or security details depend on footnotes; rows are not merged.
1 source rowRow 2 · 2020-02-29 · Tax withholding · Disposed 23,285 · Balance 244,267 F3: Of this amount, 229,267 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-29 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-29 · Exercise / conversion · Disposed 71,199 · Balance 0 F1: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F6: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-02-29 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-29 · Exercise / conversion · Disposed 5,607 · Balance 0 F1: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F6: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. |
Filing footnotes · ownership attribution and instrument terms
F1: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock.
F2: Of this amount, 252,552 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee.
F3: Of this amount, 229,267 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee.
F4: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock.
F5: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan.
F6: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 28, 2021 Filed Jun 29, 2021 19:37 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.16 | $0.00 |
DisclosureSEC source: 0001493152-21-015614 · ownership.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2031-06-28 F1 · derivative.exercise_date: The option will vest in equal quarterly installments over the next year. Read SEC document |
| September 14, 2020 Filed Sep 16, 2020 20:00 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $3.43 | $0.00 |
DisclosureSEC source: 0001493152-20-017931 · ownership.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-09-14 F1 · derivative.exercise_date: The option vests quarterly over the next year. Read SEC document |
| May 29, 2020 Filed Jun 3, 2020 21:09 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 25,000 | $0.00 Strike: $1.56 | $0.00 |
DisclosureSEC source: 0001493152-20-010504 · ownership.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 25,000 Underlying: Common Stock · 25,000 shares Expires 2030-04-14 F1 · date: The option grant was approved by the Issuer's Compensation Committee on April 14, 2020, subject to stockholder approval of an amendment to the Issuer's 2011 Incentive Plan to increase the number of authorized shares. The Issuer's stockholders approved the plan amendment on May 29, 2020. F2 · derivative.exercise_date: The option was 25% vested on April 14, 2020, and the remainder vests quarterly over the next three years. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 23:30 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 5,607 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000595 · form4-03032020_060302.xml · derivative · entry 4 Ward Robert · CIK 0001595111 · FORMER CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,607 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F6 · balance_after: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 23:30 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 71,199 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000595 · form4-03032020_060302.xml · derivative · entry 3 Ward Robert · CIK 0001595111 · FORMER CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 71,199 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F6 · balance_after: As a result of reporting person's separation from the Issuer, 25% of all unvested equity accelerated in accordance with the reporting person's employment agreement and the remaining unvested equity was forfeited. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 23:30 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 23,285 | $3.13 | $72,882.05 |
DisclosureSEC source: 0001415889-20-000595 · form4-03032020_060302.xml · nonDerivative · entry 2 Ward Robert · CIK 0001595111 · FORMER CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 244,267 F3 · balance_after: Of this amount, 229,267 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| February 29, 2020 Filed Mar 3, 2020 23:30 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 76,806 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-000595 · form4-03032020_060302.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · FORMER CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 267,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested in accordance with the reporting person's employment agreement and settled for shares of the Issuer's common stock. F2 · balance_after: Of this amount, 252,552 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| December 26, 2019 Filed Dec 27, 2019 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001569 · form4-12272019_041201.xml · derivative · entry 3 Ward Robert · CIK 0001595111 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,794 Underlying: Common Stock · 35,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F6 · balance_after: The remaining restricted stock units will vest ratably each quarter through December 26, 2021 subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| December 26, 2019 Filed Dec 27, 2019 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 15,806 | $7.26 | $114,751.56 |
DisclosureSEC source: 0001415889-19-001569 · form4-12272019_041201.xml · nonDerivative · entry 2 Ward Robert · CIK 0001595111 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 190,746 F3 · balance_after: Of this amount, 175,746 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| December 26, 2019 Filed Dec 27, 2019 21:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001569 · form4-12272019_041201.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 206,552 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F2 · balance_after: Of this amount, 191,552 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| September 26, 2019 Filed Sep 27, 2019 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001115 · form4-09272019_040902.xml · derivative · entry 3 Ward Robert · CIK 0001595111 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 320,393 Underlying: Common Stock · 35,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F6 · balance_after: The remaining restricted stock units will vest ratably each quarter through December 26, 2021 subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| September 26, 2019 Filed Sep 27, 2019 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 10,467 | $4.37 | $45,740.79 |
DisclosureSEC source: 0001415889-19-001115 · form4-09272019_040902.xml · nonDerivative · entry 2 Ward Robert · CIK 0001595111 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 170,953 F3 · balance_after: Of this amount, 155,953 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| September 26, 2019 Filed Sep 27, 2019 20:10 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-001115 · form4-09272019_040902.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · CHAIRMAN AND CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 181,420 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F2 · balance_after: Of this amount, 166,420 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:39 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000806 · form4-06272019_020637.xml · derivative · entry 3 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,992 Underlying: Common Stock · 35,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F6 · balance_after: The remaining restricted stock units will vest ratably each quarter through December 26, 2021 subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:39 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 10,467 | $9.03 | $94,517.01 |
DisclosureSEC source: 0001415889-19-000806 · form4-06272019_020637.xml · nonDerivative · entry 2 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,821 F3 · balance_after: Of this amount, 130,821 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| June 26, 2019 Filed Jun 27, 2019 21:39 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000806 · form4-06272019_020637.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 156,288 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F2 · balance_after: Of this amount, 141,288 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 20:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000399 · form4-03282019_040301.xml · derivative · entry 3 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 391,591 Underlying: Common Stock · 35,599 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F4 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F5 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F6 · balance_after: The remaining restricted stock units will vest ratably each quarter through December 26, 2021 subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 20:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 10,467 | $11.50 | $120,370.50 |
DisclosureSEC source: 0001415889-19-000399 · form4-03282019_040301.xml · nonDerivative · entry 2 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 120,689 F3 · balance_after: Of this amount, 105,689 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| March 26, 2019 Filed Mar 28, 2019 20:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 35,599 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-19-000399 · form4-03282019_040301.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,156 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F2 · balance_after: Of this amount, 116,156 shares are held by the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| January 30, 2019 Filed Feb 1, 2019 00:42 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GrantStock Options · Derivative | 226,000 | $0.00 Strike: $11.53 | $0.00 |
DisclosureSEC source: 0001415889-19-000110 · form4-01312019_040118.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 226,000 Underlying: Common Stock · 226,000 shares Expires 2029-01-30 F2 · price: The stock options were issued pursuant to the Issuer's 2018 Equity Incentive Plan. F1 · derivative.exercise_date: The option vests and becomes exercisable over a four-year period, with one-fourth of the shares of common stock underlying the options vesting on January 30, 2020, and the remainder vests in twelve equal quarterly installments thereafter. Read SEC document |
| January 02, 2019 Filed Jan 4, 2019 21:01 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 50,000 | $0.00 Strike: $0.66 | $0.00 |
DisclosureSEC source: 0001493152-19-000206 · ownership.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2029-01-02 F1 · shares: This is a long-term equity incentive award of stock options which will vest quarterly over the next three years. The first vesting will occur on 1/31/2019, and the award will be fully vested on 10/31/2021 pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| December 28, 2018 Filed Dec 28, 2018 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | GiftCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001856 · form4-12282018_041201.xml · nonDerivative · entry 3 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 95,557 F3 · kind: Gift from the Robert E. Ward 2017 Revocable Trust to a family charitable foundation of which Mr. Ward is an officer, but he is not deemed to hold a pecuniary interest in the foundation. F4 · shares: The reporting person disclaims beneficial ownership of these securities, and the filing of this report is not an admission that the reporting person is the beneficial owner of these securities for purposes of Section 16 or for any other purpose. F5 · balance_after: Reflects 80,557 shares held in the Robert E. Ward 2017 Revocable Trust. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionRestricted Stock Units · Derivative | 213,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001856 · form4-12282018_041201.xml · derivative · entry 4 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 427,190 Underlying: Common Stock · 213,595 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F6 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. F7 · price: The restricted stock units were issued pursuant to the Issuer's 2013 Share Ownership and Option Plan. F1 · derivative.exercise_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F1 · derivative.expiration_date: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F8 · balance_after: The remaining restricted stock units will vest ratably each quarter over the next three years, subject to the reporting person's continued employment with the Issuer, which vesting may be accelerated in certain circumstances. Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Tax withholdingCommon Stock | 83,038 | $12.60 | $1,046,278.80 |
DisclosureSEC source: 0001415889-18-001856 · form4-12282018_041201.xml · nonDerivative · entry 2 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 145,557 Read SEC document |
| December 26, 2018 Filed Dec 28, 2018 21:15 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | Exercise / conversionCommon Stock | 213,595 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-18-001856 · form4-12282018_041201.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · CHIEF EXECUTIVE OFFICER 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 228,595 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: The restricted stock units issued to the reporting person on December 26, 2017 have partially vested and settled for shares of the Issuer's common stock. F2 · balance_after: Of this amount, 130,557 shares have been transferred to the Robert E. Ward 2017 Revocable Trust of which Mr. Ward is a trustee. Read SEC document |
| November 08, 2018 Filed Nov 9, 2018 16:30 UTC | ONCOSEC MEDICAL Inc ONCS · Entity 117092 | GrantStock Option (Right to Buy) · Derivative | 100,000 | $0.00 Strike: $0.84 | $0.00 |
DisclosureSEC source: 0001493152-18-015582 · ownership.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 100,000 Underlying: Common Stock · 100,000 shares Expires 2028-12-08 F1 · shares: Vesting in 12 equal monthly increments, with the first 1/12th vesting on the first monthly anniversary of the Grant Date pursuant to the OncoSec Medical Incorporated 2011 Stock Incentive Plan. Read SEC document |
| May 22, 2018 Filed May 23, 2018 20:17 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 5,000 | $14.34 | $71,700.00 |
DisclosureSEC source: 0001209191-18-032580 · doc4.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Read SEC document |
| March 23, 2018 Filed Mar 26, 2018 21:13 UTC | Eloxx Pharmaceuticals, Inc. ELOX · Entity 7180 | PurchaseCommon Stock | 10,000 | $8.99 | $89,900.00 |
DisclosureSEC source: 0001209191-18-021645 · doc4.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:46 UTC | Eloxx Pharmaceuticals, Inc. SVOND · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 640,785 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 4 Ward Robert · CIK 0001595111 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,785 Underlying: Common Stock · 640,785 shares Expires 2027-12-26 F5 · derivative.exercise_date: The time-vesting options vest and become exercisable over a four (4) year period commencing on the Effective Date, with one-third (1/3) of the shares of common stock underlying the options vesting on December 26, 2018, with an additional one-twelfth (1/12) of the shares underlying the options vesting on each quarterly anniversary of the Effective Date over the course of three (3) years, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer; provided that vesting will be accelerated following the achievement of certain milestones. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:46 UTC | Eloxx Pharmaceuticals, Inc. SVOND · Entity 7180 | GrantRestricted Stock Units · Derivative | 640,785 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 3 Ward Robert · CIK 0001595111 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 640,785 Underlying: Common Stock · 640,785 shares Expires 2027-12-26 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F4 · derivative.exercise_date: The time-vesting restricted stock units vest and become exercisable over a four (4) year period commencing on December 26, 2017 (the "Effective Date"), with one-third (1/3) of the units vesting on December 26, 2018, with an additional one-twelfth (1/12) of the units vesting on each quarterly anniversary of the Effective Date over the course of three (3) years, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer; provided that vesting will be accelerated following the achievement of certain milestones. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:46 UTC | Eloxx Pharmaceuticals, Inc. SVOND · Entity 7180 | GrantStock Options (Right to Buy) · Derivative | 22,427 | $0.00 Strike: $8.00 | $0.00 |
DisclosureSEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 2 Ward Robert · CIK 0001595111 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,427 Underlying: Common Stock · 22,427 shares Expires 2027-12-26 F3 · derivative.exercise_date: The performance stock options vest and become immediately exercisable upon the date that marks the Issuer's first successful completion of a Phase-2B study with respect to any indication, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Read SEC document |
| December 26, 2017 Filed Dec 28, 2017 21:46 UTC | Eloxx Pharmaceuticals, Inc. SVOND · Entity 7180 | GrantRestricted Stock Units · Derivative | 22,427 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-065647 · tv482219_4.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director · Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,427 Underlying: Common Stock · 22,427 shares Expires 2027-12-26 F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of common stock of the Issuer. F2 · derivative.exercise_date: The performance restricted stock units vest and become immediately exercisable upon the date that marks the Issuer's first successful completion of a Phase-2B study with respect to any indication, subject, with limited exceptions, to the Reporting Person's continued employment with the Issuer. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 16:31 UTC | Radius Health, Inc. RDUS · Entity 124173 | GrantStock Option (Right to Buy) · Derivative | 187,800 | $0.00 Strike: $45.65 | $0.00 |
DisclosureSEC source: 0001209191-17-013274 · doc4.xml · derivative · entry 1 Ward Robert · CIK 0001595111 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 187,800 Underlying: Common Stock · 187,800 shares Expires 2027-02-16 F1 · derivative.exercise_date: 25% of the shares subject to the stock option shall vest on February 17, 2018 and the remaining shares shall vest in substantially equal monthly installments over the following three years. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 21:54 UTC | Radius Health, Inc. RDUS · Entity 124173 | Exercise / conversionStock Option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $7.80 | $0.00 |
DisclosureSEC source: 0001104659-16-152030 · a4.xml · derivative · entry 2 Ward Robert · CIK 0001595111 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 733,785 Underlying: Common Stock · 10,000 shares Expires 2024-02-15 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: The exercise price and number of derivative securities was adjusted to reflect the stock split that occurred on April 24, 2014. F1 · shares: The exercise price and number of derivative securities was adjusted to reflect the stock split that occurred on April 24, 2014. F2 · derivative.exercise_date: This stock option vested as to 25% of the underlying shares upon consummation of the Issuer's initial public offering on June 6, 2014 and as to an additional 18.75% of the underlying shares on December 16, 2014. The remainder of the stock option vests in substantially equal installments on the 16th day of each of the 36 consecutive months beginning January 16, 2015. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 21:54 UTC | Radius Health, Inc. RDUS · Entity 124173 | Exercise / conversionCommon Stock | 10,000 | $7.80 | $78,000.00 |
DisclosureSEC source: 0001104659-16-152030 · a4.xml · nonDerivative · entry 1 Ward Robert · CIK 0001595111 · Director · President & CEO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.